

**UNIVERSITÀ DEGLI STUDI DI MILANO**

selezione pubblica per n.\_1\_ posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale \_\_ 06/D6 - NEUROLOGIA \_\_ , settore scientifico-disciplinare \_\_\_\_\_ MED/26 - NEUROLOGIA \_\_\_\_\_, presso il Dipartimento di \_\_\_\_\_ Scienze Biomediche, Chirurgiche ed Odontoiatriche\_\_\_\_, (avviso bando pubblicato sulla G.U. n. \_\_59\_\_ del \_\_26/07/2022) Codice concorso \_\_5068\_\_

## Antonio Carotenuto

### CURRICULUM VITAE

**INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)**

COGNOME	CAROTENUTO
NOME	ANTONIO
DATA DI NASCITA	22 LUGLIO 1987

**TITOLI****TITOLO DI STUDIO**

(indicare la Laurea conseguita inserendo titolo, Ateneo, data di conseguimento, ecc.)

- Laurea in Medicina e Chirurgia conseguita presso l'Università degli Studi di Napoli 'Federico II' in data 27/07/2012 con votazione 110/110 e Lode con una tesi dal titolo "Blocco della differenziazione oligodendrocitica: nuove prospettive per l'eziopatogenesi della sclerosi multipla"

**TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO**

(inserire titolo, ente, data di conseguimento, ecc.)

- Specializzazione in Neurologia conseguita presso l'Università degli Studi di Napoli 'Federico II' in data 26/07/2018 con votazione 50/50 e Lode con una tesi dal titolo "Valutazione in vivo del danno mielinico in sclerosi multipla: studio PET-MRI con [18F]florbetaben"
- Dottorato di Ricerca in Neuroscienze conseguito presso l'Università Degli Studi di Napoli 'Federico II' in data 28/04/2022 con giudizio OTTIMO con una tesi dal titolo "In vivo assessment of glymphatic system in multiple sclerosis"

**ATTIVITÀ DIDATTICA A LIVELLO UNIVERSITARIO IN ITALIA O ALL'ESTERO**

(inserire periodo [gg/mm/aa inizio e fine], anno accademico, ateneo, corso laurea, numero ore, ecc.)

Docente per Master II livello 'Alta formazione per l'integrazione tra cure e ricerca nella sclerosi multipla' condotto presso Centro Sclerosi Multipla, Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche dell'Università degli Studi di Napoli "Federico II", Via Pansini 5 - 80131, Napoli durante l'anno accademico 2019/2020 della durata di 1 anno (CFU 60, ore 1500).

**DOCUMENTATA ATTIVITÀ DI FORMAZIONE O DI RICERCA PRESSO QUALIFICATI ISTITUTI ITALIANI O STRANIERI;**

*(inserire anno accademico, ente, corso, periodo, ecc.)*

- Clinical Research Fellowship presso Università Vita-Salute San Raffele di Milano dal 01/09/2020 al 31/08/2022
- Clinical Research Fellowship presso King's College London, Londra dal 01/07/2018 al 01/07/2019

**DOCUMENTATA ATTIVITÀ IN CAMPO CLINICO**

*(indicare, data, durata, ruolo, ente presso il quale si è prestata attività assistenziale, ecc.)*

- Clinical Fellowship at Ospedale Pediatrico Bambino Gesù dal 01-03-2010 al 31-05-2015
- Clinical Fellowship in Neurologia Pediatrica (Supervisor: Prof. Patrick Van Bogaert), Hôpital Erasme (Université libre de Bruxelles) dal 07-02-2011 al 29-07-2011

**REALIZZAZIONE DI ATTIVITÀ PROGETTUALE**

*(indicare, data, progetto, ecc.)*

- Coordinamento e finalizzazione progetto internazionale dal titolo 'Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®' finanziato dal 2014 Almirall MS Spasticity Research Grant.
- Coordinamento e finalizzazione progetto internazionale dal titolo 'Network Centrality in Multiple Sclerosis' finanziato dal 2020 ECTRIMS-MAGNIMS International Fellowship.
- Coordinamento e finalizzazione progetto nazionale non sponsorizzato dal titolo 'Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis' in seno al Cogniped Study Group

**ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI, O PARTECIPAZIONE AGLI STESSI**

*(per ciascuna voce inserire anno, ruolo, gruppo di ricerca, ecc.)*

- Representative for EAN Multiple Sclerosis Scientific Panel: Diagnostic and therapeutic guidelines dal 14-10-2016 ad oggi
- Representative for EAN Scientific Panel membership: guidelines for Neuroimaging dal 14-10-2021 ad oggi
- Coordinamento e finalizzazione progetto internazionale dal titolo 'Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®' finanziato dal 2014 Almirall MS Spasticity Research Grant.
- Coordinamento e finalizzazione progetto internazionale dal titolo 'Network Centrality in Multiple Sclerosis' finanziato dal 2020 ECTRIMS-MAGNIMS International Fellowship.

**ATTIVITÀ DI RELATORE A CONGRESSI E CONVEGNI NAZIONALI E INTERNAZIONALI**

*(inserire titolo congresso/convegno, data, ecc.)*

- Relatore per 8<sup>th</sup> Congress of the European Academy of Neurology - Europe 2022 dal 24-06-2022 al 28-06-2022
- Relatore per 37<sup>th</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis dal 13-10-2021 al 15-10-2021
- Relatore per XXV World Congress of Neurology dal 03-10-2021 al 07-10-2021
- Relatore per 7<sup>th</sup> Congress of the European Academy of Neurology – Virtual 2021 dal 19-06-2021 al 22-06-2021
- Relatore per 'Highlights in Neurology III dal 03-09-2020 al 05-09-2020
- Relatore al 5° Annual meeting for the International Society for Neurovascular Diseases dal 27-03-2015 al 27-03-2015

- Relatore presso il 3<sup>rd</sup> Congress of the European Academy of Neurology dal 24-06-2017 al 27-06-2017
- Relatore per il congresso JAMS dal 23-05-2019 al 25-05-2019
- Relatore per 'La sclerosi Multipla in età evolutiva' dal 22-11-2019 al 22-11-2019

#### **CONSEGUIMENTO DI PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA** (inserire premio, data, ente organizzatore, ecc.)

- 'Abilitazione Scientifica Nazionale' a Professore di Seconda Fascia in Neurologia (06/D6) in Aprile 2021
- ECTRIMS-MAGNIMS Fellowship in Magnetic Resonance Imaging in Multiple Sclerosis per il progetto "Network centrality in Multiple Sclerosis"
- Almirall Spasticity Research Grant 4th Edition il 11-05-2014

#### **PRODUZIONE SCIENTIFICA**

##### **PUBBLICAZIONI SCIENTIFICHE**

(per ciascuna pubblicazione indicare: nomi degli autori, titolo completo, casa editrice, data e luogo di pubblicazione, codice ISBN, ISSN, DOI o altro equivalente)

1. Carotenuto A, Valsasina P, Schoonheim MM, Geurts JJG, Barkhof F, Gallo A, Tedeschi G, Tommasin S, Pantano P, Filippi M, Rocca MA, on behalf of the MAGNIMS Study Group. Association of functional network abnormalities with disease phenotype, clinical and cognitive disability, and structural damage in patients with multiple sclerosis. *Neurology*. In press.
2. Cacciaguerra L, Carotenuto A, Pagani E, Mistri D, Radaelli M, Martinelli V, et al. Magnetic Resonance Imaging Evaluation of Perivascular Space Abnormalities in Neuromyelitis Optica. *Ann Neurol* 2022;92(2):173-183.
3. Zappulo E, Buonomo AR, Moccia M, Pinchera B, Villari R, Petracca M, et al. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. *Mult Scler Relat Disord* 2022;63.
4. Moccia M, Loperto I, Santoni L, Masera S, Affinito G, Carotenuto A, et al. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis. *Neurodegenerative Dis Manage* 2022;12(3):109-116.
5. Lanzillo R, Carotenuto A, Signoriello E, Iodice R, Miele G, Bisecco A, et al. Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. *J Clin Med* 2022;11(8).
6. Moccia M, Affinito G, Ronga B, Giordana R, Fumo MG, Lanzillo R, et al. Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy). *Mult Scler J* 2022;28(4):597-607.
7. Carotenuto A, Valsasina P, Hidalgo de la Cruz M, Cacciaguerra L, Preziosa P, Marchesi O, et al. Divergent time-varying connectivity of thalamic sub-regions characterizes clinical phenotypes and cognitive status in multiple sclerosis. *Mol Psychiatry* 2022;27(3):1765-1773.
8. Disanto G, Moccia M, Sacco R, Spiezia AL, Carotenuto A, Brescia Morra V, et al. Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. *Mult Scler Relat Disord* 2022;58.

9. Carotenuto A, Costabile T, Pontillo G, Moccia M, Falco F, Petracca M, et al. Cognitive trajectories in multiple sclerosis: a long-term follow-up study. *Neurol Sci* 2022;43(2):1215-1222.
10. Iaffaldano P, Lucisano G, Guerra T, Patti F, Onofrij M, Brescia Morra V, et al. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. *Mult Scler J* 2022.
11. Moccia M, Affinito G, Berera G, Marrazzo G, Piscitelli R, Carotenuto A, et al. Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy. *J Neurol* 2022.
12. Rosa L, Scandurra C, Chiodi A, Petracca M, Costabile T, Lauro F, et al. Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience. *J Clin Psychol Med Settings* 2022.
13. Spiezia AL, Cerbone V, Molinari EA, Capasso N, Lanzillo R, Carotenuto A, et al. Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. *Mult Scler Relat Disord* 2022;57.
14. Russo CV, Saccà F, Frau J, Annovazzi P, Signoriello E, Bonavita S, et al. A real-world study of alemtuzumab in a cohort of Italian patients. *Eur J Neurol* 2022;29(1):257-266.
15. Signoriello E, Lus G, Bonavita S, Lanzillo R, Saccà F, Landi D, et al. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. *Mult Scler J* 2022;28(1):93-101.
16. Carotenuto A, Costabile T, Moccia M, Falco F, Petracca M, Satelliti B, et al. Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis. *Int Neurourology J* 2021;25(4):310-318.
17. Montorio D, Lanzillo R, Carotenuto A, Petracca M, Moccia M, Criscuolo C, et al. Retinal and choriocapillary vascular changes in early stages of multiple sclerosis: A prospective study. *J Clin Med* 2021;10(24).
18. Vola EA, Petracca M, Coccozza S, De Angelis M, Carotenuto A, Pontillo G, et al. Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions. *BMC Neurol* 2021;21(1).
19. Pontillo G, Tommasin S, Cuocolo R, Petracca M, Petsas N, Uggà L, et al. A combined radiomics and machine learning approach to overcome the clinico-radiologic paradox in multiple sclerosis. *Am J Neuroradiol* 2021;42(11).
20. Petracca M, Quarantelli M, Moccia M, Vacca G, Satelliti B, D'Ambrosio G, et al. Prospective study to evaluate efficacy, safety and tolerability of dietary supplement of Curcumin (BCM95) in subjects with Active relapsing Multiple Sclerosis treated with subcutaneous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial. *Mult Scler Relat Disord* 2021;56.
21. Costabile T, Carotenuto A, Lavorgna L, Borriello G, Moiola L, Inglese M, et al. COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. *Eur J Neurol* 2021;28(10):3375-3383.
22. Moccia M, Affinito G, Capacchione A, Lanzillo R, Carotenuto A, Montella E, et al. Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data. *PLoS ONE* 2021;16(9 September).
23. Cortese R, Carotenuto A, Di Filippo M, Lanzillo R. Editorial: Cognition in Multiple Sclerosis. *Front Neurol* 2021;12.
24. Valeria RC, Roberta L, Francesco S, Marcello M, Antonio C, Vincenzo BM. Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series. *Neurol Sci* 2021;42(8):3427-3430.

25. Carotenuto A, De Giglio L, Chiodi A, Petracca M, Rosa L, Bianchi M, et al. Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19. *Neurol Sci* 2021;42(7):2903-2910.
26. De Angelis M, Lavorgna L, Carotenuto A, Petruzzo M, Lanzillo R, Morra VB, et al. Digital technology in clinical trials for multiple sclerosis: Systematic review. *J Clin Med* 2021;10(11).
27. Ghai S, Kasilingam E, Lanzillo R, Malenica M, van Pesch V, Burke NC, et al. Needs and experiences of children and adolescents with pediatric multiple sclerosis and their caregivers: A systematic review. *Child* 2021;8(6).
28. Capasso N, Nozzolillo A, Scalia G, Lanzillo R, Carotenuto A, De Angelis M, et al. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis. *Mult Scler Relat Disord* 2021;49.
29. Carotenuto A, Scandurra C, Costabile T, Lavorgna L, Borriello G, Moiola L, et al. Physical exercise moderates the effects of disability on depression in people with multiple sclerosis during the covid-19 outbreak. *J Clin Med* 2021;10(6):1-7.
30. Petracca M, Pontillo G, Moccia M, Carotenuto A, Coccozza S, Lanzillo R, et al. Neuroimaging correlates of cognitive dysfunction in adults with multiple sclerosis. *Brain Sci* 2021;11(3).
31. Petruzzo M, Reia A, Maniscalco GT, Luiso F, Lanzillo R, Russo CV, et al. The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis. *Eur J Neurol* 2021;28(3):893-900.
32. Buonomo AR, Viceconte G, Zappulo E, Maraolo AE, Russo CV, Carotenuto A, et al. Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies. *Expert Opin Drug Saf* 2021;20(10):1237-1246.
33. Reia A, Petruzzo M, Falco F, Costabile T, Conenna M, Carotenuto A, et al. A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis. *Brain Sci* 2021;11(4).
34. Capasso N, Palladino R, Montella E, Pennino F, Lanzillo R, Carotenuto A, et al. Prevalence of SARS-CoV-2 antibodies in multiple sclerosis: The hidden part of the ICEBERG. *J Clin Med* 2020;9(12):1-11.
35. D'Amico E, Zanghì A, Sciandra M, Lanzillo R, Callari G, Cortese A, et al. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. *J Neurol* 2020;267(10):3008-3020.
36. Comi G, Pozzilli C, Morra VB, Bertolotto A, Sangalli F, Prosperini L, et al. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. *Neurol Sci* 2020;41(10):2843-2851.
37. Moccia M, Frau J, Carotenuto A, Butera C, Coghe G, Barbero P, et al. Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. *Neurol Sci* 2020;41(10):2781-2792.
38. Moccia M, Loperto I, Lanzillo R, Capacchione A, Carotenuto A, Triassi M, et al. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: A population-based study in the Campania region (southern Italy). *BMC Health Serv Res* 2020;20(1).
39. Carotenuto A., Signoriello, E., Lanzillo, R., Vania, Y., Moccia, M., Bonavita, S., . . . Brescia Morra, V. (2020). Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis. *Multiple Sclerosis and Related Disorders*, 43 doi:10.1016/j.msard.2020.102211Pontillo G, Coccozza S, Di Stasi M, Carotenuto A, Paoletta C, Cipullo MB, et al. 2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis. *Eur Radiol* 2020;30(7):3813-3822.

40. Carotenuto A, Wilson H, Giordano B, Caminiti SP, Chappell Z, Williams SCR, et al. Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. *J Neurol* 2020;267(7):2042-2053.
41. Cennamo G, Carotenuto A, Montorio D, Petracca M, Moccia M, Melenzane A, et al. Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis. *Front Neurol* 2020;11.
42. Moccia M, Lanzillo R, Petruzzo M, Nozzolillo A, De Angelis M, Carotenuto A, et al. Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials. *Front Neurol* 2020;11.
43. Criscuolo C, Cennamo G, Montorio D, Carotenuto A, Strianese A, Salvatore E, et al. Assessment of retinal vascular network in amnesic mild cognitive impairment by optical coherence tomography angiography. *PLoS ONE* 2020;15(6).
44. Carotenuto A, Costabile T, De Lucia M, Moccia M, Falco F, Petruzzo M, et al. Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study. *J Neurol* 2020;267(6):1737-1743.
45. Carotenuto A, Giordano B, Dervenoulas G, Wilson H, Veronese M, Chappell Z, et al. [18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. *Eur J Nucl Med Mol Imaging* 2020;47(2):366-378.
46. Lanzillo R, Moccia M, Palladino R, Signoriello E, Carotenuto A, Maniscalco GT, et al. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study. *Mult Scler Relat Disord* 2020;38.
47. Margoni M, Carotenuto A. Very late-onset recurrent myelitis in a patient diagnosed with antiphospholipid syndrome: A puzzle of autoimmunity. *J Neuroimmunol* 2019;337.
48. Carotenuto A, Moccia M, Costabile T, Signoriello E, Paolicelli D, Simone M, et al. Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis. *Sci Rep* 2019;9(1).
49. Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, et al. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study. *J Neurol* 2019;266(10):2440-2446.
50. Falco F, Moccia M, Chiodi A, Carotenuto A, D’Amelio A, Rosa L, et al. Correction to: Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education (*Neurological Sciences*, (2019), 40, 4, (713-717), 10.1007/s10072-019-3712-3). *Neurol Sci* 2019;40(5):1099-1100.
51. Falco F, Moccia M, Chiodi A, Carotenuto A, D’Amelio A, Rosa L, et al. Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education. *Neurol Sci* 2019;40(4):713-717.
52. Lanzillo R, Moccia M, Russo CV, Carotenuto A, Nozzolillo A, Petruzzo M, et al. Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin. *Mult Scler Relat Disord* 2019;28:193-196.
53. Iovino A, Aruta F, Carotenuto A, Manganelli F, Iodice R. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis. *Mult Scler Relat Disord* 2019;28:98-100.
54. Megna R, Alfano B, Lanzillo R, Costabile T, Commerci M, Vacca G, et al. Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment. *J Neurol* 2019;266(2):361-368.
55. Moccia M, Capacchione A, Lanzillo R, Carbone F, Micillo T, Perna F, et al. Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis. *Ther Adv Neurol Disord* 2019;12.

56. Buonomo AR, Saccà F, Zappulo E, De Zottis F, Lanzillo R, Gentile I, et al. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis. *Mult Scler Relat Disord* 2019;27:44-45.
57. Carotenuto A, Costabile T, Moccia M, Falco F, Scala MR, Russo CV, et al. Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis. *Mult Scler Relat Disord* 2019;27:1-6.
58. Lanzillo R, Cennamo G, Moccia M, Criscuolo C, Carotenuto A, Frattaruolo N, et al. Retinal vascular density in multiple sclerosis: a 1-year follow-up. *Eur J Neurol* 2019;26(1):198-201.
59. Lanzillo R, Cennamo G, Criscuolo C, Carotenuto A, Velotti N, Sparnelli F, et al. Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis. *Mult Scler J* 2018;24(13):1706-1714.
60. Carotenuto A, Cocozza S, Quarantelli M, Arcara G, Lanzillo R, Brescia Morra V, et al. Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction. *Brain Lang* 2018;185:47-53.
61. Vacchiano V, Frattaruolo N, Mancinelli L, Foschi M, Carotenuto A, Scandellari C, et al. Teeth loss after teriflunomide treatment: Casual or causal? A short case series. *Mult Scler Relat Disord* 2018;24:120-122.
62. Moccia M, Albero R, Lanzillo R, Saccà F, De Rosa A, Russo CV, et al. Cardiovascular profile improvement during Natalizumab treatment. *Metab Brain Dis* 2018;33(3):981-986.
63. Carotenuto A, Arcara G, Orefice G, Cerillo I, Giannino V, Rasulo M, et al. Communication in Multiple Sclerosis: Pragmatic Deficit and its Relation with Cognition and Social Cognition. *Arch Clin Neuropsychol* 2018;33(2):194-205.
64. Carotenuto A. Look beyond the door, not through the keyhole: evidence from a cognitive assessment including social cognition evaluation in multiple sclerosis. *Eur J Neurol* 2018;25(2):205-206.
65. Moccia M, Palladino R, Carotenuto A, Saccà F, Russo CV, Lanzillo R, et al. A 8-year retrospective cohort study comparing Interferon- $\beta$  formulations for relapsing-remitting multiple sclerosis. *Mult Scler Relat Disord* 2018;19:50-54.
66. Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De Rosa V, et al. Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a. *Clin Immunol* 2017;183:249-253.
67. Lanzillo R, Carotenuto A, Moccia M, Saccà F, Russo CV, Massarelli M, et al. A longitudinal real-life comparison study of natalizumab and fingolimod. *Acta Neurol Scand* 2017;136(3):217-222.
68. Carotenuto A, Scalia G, Ausiello F, Moccia M, Russo CV, Saccà F, et al. CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. *J Neuroimmunol* 2017;309:47-50.
69. Saccà F, Costabile T, Carotenuto A, Lanzillo R, Moccia M, Pane C, et al. The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests. *Mult Scler* 2017;23(9):1289-1296.
70. Carotenuto A, Iodice R, Petracca M, Inglese M, Cerillo I, Cocozza S, et al. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®. *Acta Neurol Scand* 2017;135(4):442-448.
71. Lanzillo R, Di Somma C, Quarantelli M, Carotenuto A, Pivonello C, Moccia M, et al. Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon  $\beta$ -1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis. *Eur J Neurol* 2017;24(2):446-449.
72. Moccia M, Palladino R, Lanzillo R, Carotenuto A, Russo CV, Triassi M, et al. Healthcare Costs for treating relapsing multiple sclerosis and the risk of progression: A retrospective Italian cohort study from 2001 to 2015. *PLoS ONE* 2017;12(1).

73. Moccia M, Quarantelli M, Lanzillo R, Cocozza S, Carotenuto A, Carotenuto B, et al. Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression. *Eur J Neurol* 2017;24(1):195-204.
74. Moccia M, Palladino R, Carotenuto A, Russo CV, Triassi M, Lanzillo R, et al. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. *Mult Scler Relat Disord* 2016;10:90-96.
75. Saccà F, Pane C, Carotenuto A, Massarelli M, Lanzillo R, Florio EB, et al. The use of medical-grade cannabis in patients non-responders to Nabiximols. *J Neurol Sci* 2016;368:349-351.
76. Iodice R, Carotenuto A, Dubbioso R, Cerillo I, Santoro L, Manganeli F. Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy. *J Neurol Sci* 2016;365:143-146.
77. Signoriello E, Lanzillo R, Brescia Morra V, Di Iorio G, Fratta M, Carotenuto A, et al. Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. *Mult Scler* 2016;22(7):921-925.
78. Orefice NS, Carotenuto A, Mangone G, Bues B, Rehm R, Cerillo I, et al. Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis. *J Steroid Biochem Mol Biol* 2016;159:1-7.
79. Moccia M, Lanzillo R, Palladino R, Chang KC-, Costabile T, Russo C, et al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. *Mult Scler* 2016;22(5):659-667.
80. Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon- $\beta$ 1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis. *Neurotherapeutics* 2016;13(2):428-438.
81. Cennamo G, Romano MR, Vecchio EC, Minervino C, Della Guardia C, Velotti N, et al. Anatomical and functional retinal changes in multiple sclerosis. *Eye* 2016;30(3):456-462.
82. Moccia M, Carotenuto A, Massarelli M, Lanzillo R, Brescia Morra V. Can people with multiple sclerosis actually understand what they read in the Internet age? *J Clin Neurosci* 2016;25:167-168.
83. Spina E, Carotenuto A, Aceto MG, Cerillo I, Silvestre F, Arace F, et al. The effects of mechanical focal vibration on walking impairment in multiple sclerosis patients: A randomized, double-blinded vs placebo study. *Restor Neurol Neurosci* 2016;34(5):869-876.
84. Lanzillo R, Chiodi A, Carotenuto A, Magri V, Napolitano A, Liuzzi R, et al. Quality of life and cognitive functions in early onset multiple sclerosis. *Eur J Paediatr Neurol* 2016;20(1):158-163.
85. Moccia M, Erro R, Montella S, Carotenuto A, Pappatà S, Orefice G. Diagnostic challenges of Parkinsonism occurring in multiple sclerosis. *Acta Neurol Belg* 2015;115(3):513-515.
86. Damiano S, Sasso A, De Felice B, Terrazzano G, Bresciamorra V, Carotenuto A, et al. The IFN- $\beta$  1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells. *Brain Res Bull* 2015;118:1-6.
87. Lanzillo R, Moccia M, Carotenuto A, Vacchiano V, Satelliti B, Panetta V, et al. Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study. *Mult Scler* 2015;21(9):1215.
88. Moccia M, Lanzillo R, Palladino R, Maniscalco GT, De Rosa A, Russo C, et al. The Framingham cardiovascular risk score in multiple sclerosis. *Eur J Neurol* 2015;22(8):1176-1183.



89. Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, et al. Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study. *J Neurol* 2015;262(4):961-967.
90. Moccia M, Lanzillo R, Palladino R, Russo C, Carotenuto A, Massarelli M, et al. Uric acid: A potential biomarker of multiple sclerosis and of its disability. *Clin Chem Lab Med* 2015;53(5):753-759.
91. Lanzillo R, Moccia M, Carotenuto A, Vacchiano V, Satelliti B, Panetta V, et al. Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study. *Mult Scler J* 2015;21(9):1215-1216.
92. Moccia M, Picillo M, Carotenuto A, Spina E, Orefice G. Serpentine tongue in long-term metoclopramide treatment. *Neurol Psychiatry Brain Res* 2014;20(4):93-95.
93. Carotenuto A, Barbato F, Vacca G, Barbieri F, Orefice G. Idiopathic intracranial hypertension in a patient with thyroid papillary carcinoma. *Neurol Sci* 2014;35(1):109-111.
94. Moccia M, Picillo M, Carotenuto A, Barbato F, Gentile I, Orefice G. Movement disorders as presenting symptoms of AIDS. *Basal Ganglia* 2013;3(3):175-178.
95. Carotenuto A, Iodice R, Barbato F, Orefice NS, Orefice G. Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate. *J Neurol Sci* 2013;331(1-2):172-173.
96. Lanzillo R, Bonavita S, Quarantelli M, Vacca G, Lus G, Amato L, et al. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. *Neurol Sci* 2013;34(4):521-528.
97. Specchio N, Trivisano M, Serino D, Cappelletti S, Carotenuto A, Claps D, et al. Epilepsy in ring 14 chromosome syndrome. *Epilepsy Behav* 2012;25(4):585-592.
98. Specchio N, Balestri M, Trivisano M, Japaridze N, Striano P, Carotenuto A, et al. Electroencephalographic features in Dravet syndrome: Five-year follow-up study in 22 patients. *J Child Neurol* 2012;27(4):439-444.
99. Specchio N, Carotenuto A, Trivisano M, Cappelletti S, Vigeveno F, Fusco L. Ictal yawning in a patient with drug-resistant focal epilepsy: Video/EEG documentation and review of literature reports. *Epilepsy Behav* 2011;22(3):602-605.
100. Specchio N, Carotenuto A, Trivisano M, Cappelletti S, Vigeveno F, Fusco L. Prolonged episode of dystonia and dyskinesia resembling status epilepticus following acute intrathecal baclofen withdrawal. *Epilepsy Behav* 2011;21(3):321-323.
101. Specchio N, Carotenuto A, Trivisano M, Cappelletti S, Digilio C, Capolino R, et al. Ring 21 chromosome presenting with epilepsy and intellectual disability: Clinical report and review of the literature. *Am J Med Genet Part A* 2011;155(4):911-914.

Data

05/09/2022

Luogo

Napoli

